Immuron reported a third-quarter 66 percent increase in sales. Immuron is a Biopharmaceutical company focused on digestive supplements.
Q3 global sales reaped AUD$616,000 compared to 2018’s Q3 Global sales of $371,000. Year-to-date sales at 31 March reached AUD1.7M, a 23 percent increase.
Q3 sales of the company’s product most popular product, Travelan, surged 73 percent in Australia. US sales of Travelan were similar at 60 percent growth.
The company recently began airing an ad spotlight with Chemist Warehouse for Travelan.
Travelan has also been featured in a partnership with US travel medicine network Passport Health.
Immuron CEO Gary Jacob says the company will focus on continuing the expansion of Travelan sales growth.
“[Travelan sales] within existing markets, coupled with our re-entry into Canada puts us in a strong position for continued growth,” he said.
Immuron rose 16.7 percent in the ASX today.